bioAffinity Technologies, Inc. (Nasdaq: BIAF) announced on November 11, 2026, that it achieved a record number of tests for its CyPath Lung product in October 2026. The filing details that 235 CyPath Lung tests were performed during that month, representing a 29% increase compared to the same period in the previous year.

The October testing volume accounted for approximately 45% of the total number of tests performed in the third quarter of 2026. The company stated that this growth reflects continued utilization by both established and newly ordering physicians. Maria Zannes, President and Chief Executive Officer, noted that the results demonstrate the effectiveness of efforts to expand the commercial reach of the test.

CyPath Lung is a noninvasive test designed to help physicians assess the likelihood of lung cancer by analyzing cell populations in sputum using flow cytometry and proprietary artificial intelligence. The test is marketed as a Laboratory Developed Test (LDT) by Precision Pathology Laboratory Services, a subsidiary of bioAffinity Technologies. In a published clinical trial involving high-risk patients with small indeterminate lung nodules, the test demonstrated 92% sensitivity, 87% specificity, and 99% negative predictive value.

The company indicated that it is expanding its sales team and working with patient advocacy organizations to strengthen connections within the lung cancer community. bioAffinity is also advancing research to apply its proprietary technology platform to asthma and COPD.